|
KR100908114B1
(ko)
*
|
2002-03-09 |
2009-07-16 |
삼성전자주식회사 |
스케일러블 무손실 오디오 부호화/복호화 장치 및 그 방법
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP3693017A1
(en)
|
2010-12-14 |
2020-08-12 |
University of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
EP2697397B1
(en)
|
2011-04-15 |
2017-04-05 |
The Johns Hopkins University |
Safe sequencing system
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
US9107904B2
(en)
|
2012-04-05 |
2015-08-18 |
Massachusetts Institute Of Technology |
Immunostimulatory compositions and methods of use thereof
|
|
EA201992742A3
(ru)
*
|
2012-07-13 |
2020-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Применение cart19 для истощения нормальных b-клеток для индукции толерантности
|
|
CA2878856A1
(en)
*
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating car t cells
|
|
EP2912468B1
(en)
|
2012-10-29 |
2018-09-12 |
The Johns Hopkins University |
Papanicolaou test for ovarian and endometrial cancers
|
|
ES2949648T3
(es)
|
2012-12-20 |
2023-10-02 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
MX374929B
(es)
|
2013-02-20 |
2025-03-06 |
Novartis Ag |
RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
|
|
HRP20201419T1
(hr)
|
2013-02-26 |
2020-12-11 |
Memorial Sloan Kettering Cancer Center |
Pripravci i postupci za imunoterapiju
|
|
EP2968345B1
(en)
*
|
2013-03-13 |
2017-12-13 |
The Regents of The University of Michigan |
Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases
|
|
HK1217000A1
(zh)
*
|
2013-03-14 |
2016-12-16 |
Bellicum Pharmaceuticals, Inc. |
控制t细胞增殖的方法
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
DK3027204T3
(da)
*
|
2013-07-29 |
2022-04-19 |
2Seventy Bio Inc |
Flerdelte signaleringsproteiner og anvendelser deraf
|
|
JP6637415B2
(ja)
*
|
2013-10-15 |
2020-01-29 |
ザ スクリプス リサーチ インスティテュート |
キメラ抗原受容体ｔ細胞スイッチおよびその使用
|
|
WO2015057834A1
(en)
*
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
HRP20201906T1
(hr)
*
|
2013-12-20 |
2021-04-02 |
Fred Hutchinson Cancer Research Center |
Označene kimerne efektorske molekule i njihovi receptori
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
AU2015218396A1
(en)
|
2014-02-14 |
2016-08-11 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating T cells using an inducible chimeric polypeptide
|
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
|
HUE054588T2
(hu)
|
2014-04-07 |
2021-09-28 |
Novartis Ag |
Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
|
|
WO2015188191A1
(en)
*
|
2014-06-06 |
2015-12-10 |
Wong Wilson W |
Dna recombinase circuits for logical control of gene expression
|
|
CN105194661B
(zh)
*
|
2014-06-26 |
2019-05-03 |
科济生物医药（上海）有限公司 |
时空可调性抑制病理性靶细胞的系统
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
CN107531800B
(zh)
*
|
2014-07-25 |
2021-08-10 |
赛拉福柯蒂斯公司 |
用于嵌合抗原受体分子的调控表达的慢病毒载体
|
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
JP6868554B2
(ja)
|
2014-09-02 |
2021-05-12 |
ベリカム ファーマシューティカルズ， インコーポレイテッド |
ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
|
|
WO2016044605A1
(en)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2016057705A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
ES2927366T3
(es)
*
|
2014-10-09 |
2022-11-04 |
Univ Yamaguchi |
Vector de expresión de CAR y células T que expresan CAR
|
|
ES2692206T3
(es)
|
2014-11-26 |
2018-11-30 |
Miltenyi Biotec Gmbh |
Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
ES2923895T3
(es)
|
2015-02-27 |
2022-10-03 |
Icell Gene Therapeutics Llc |
Receptores de antígeno quimérico (CARS) dirigidos a neoplasisas malignas hematológicas, composiciones y métodos de uso de los mismos
|
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
|
AU2016243124A1
(en)
*
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
CAR T-cell therapy directed to LHR for the treatment of solid tumors
|
|
CN119925616A
(zh)
|
2015-04-08 |
2025-05-06 |
诺华股份有限公司 |
Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
|
|
US11091546B2
(en)
*
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN107849112B
(zh)
|
2015-06-25 |
2022-04-01 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
TWI859112B
(zh)
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
WO2017027653A1
(en)
|
2015-08-11 |
2017-02-16 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
|
EP3339320A4
(en)
*
|
2015-08-17 |
2019-01-23 |
Seoul National University R&DB Foundation |
CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF
|
|
US20180243340A1
(en)
*
|
2015-08-24 |
2018-08-30 |
University Of Houston System |
Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
WO2017041143A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Ctm@Crc Ltd. |
Chimeric antigen receptors and uses thereof
|
|
EP3569244A1
(en)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
HK1259190A1
(zh)
*
|
2015-11-23 |
2019-11-29 |
波士顿大学董事会 |
嵌合抗原受体相关的方法和组合物
|
|
CA3006432A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
|
US11377481B2
(en)
*
|
2015-12-22 |
2022-07-05 |
The Trustees Of The University Of Pennsylvania |
SpyCatcher and SpyTag: universal immune receptors for T cells
|
|
WO2017112877A1
(en)
*
|
2015-12-22 |
2017-06-29 |
Icell Gene Therapeutics, Llc |
Chimeric antigen receptors and enhancement of anti-tumor activity
|
|
US11413309B2
(en)
|
2016-01-20 |
2022-08-16 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
CN116376826A
(zh)
*
|
2016-01-20 |
2023-07-04 |
菲特治疗公司 |
用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
|
|
CN108697798A
(zh)
*
|
2016-02-16 |
2018-10-23 |
达纳-法伯癌症研究所有限公司 |
免疫疗法组合物及方法
|
|
RU2770812C2
(ru)
*
|
2016-03-17 |
2022-04-22 |
Ямагути Университи |
Иммунокомпетентная клетка и экспрессирующий вектор, экспрессирующие регуляторные факторы иммунной функции
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2017177149A2
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
EP4353750A3
(en)
|
2016-06-24 |
2024-07-24 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
ES3030503T3
(en)
|
2016-10-19 |
2025-06-30 |
Scripps Research Inst |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
US10617720B2
(en)
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
EP3315511A1
(en)
|
2016-10-29 |
2018-05-02 |
Miltenyi Biotec GmbH |
Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
CN110475857B
(zh)
|
2017-01-05 |
2023-07-18 |
韩国生命工学研究院 |
表达抗-可替宁嵌合抗原受体的天然杀伤细胞
|
|
KR102122546B1
(ko)
*
|
2017-01-05 |
2020-06-15 |
한국생명공학연구원 |
항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
ES2988795T3
(es)
|
2017-02-27 |
2024-11-21 |
Juno Therapeutics Inc |
Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AU2018250336B2
(en)
|
2017-04-07 |
2025-02-20 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
MX2019012189A
(es)
|
2017-04-14 |
2020-12-10 |
Juno Therapeutics Inc |
Metodos para valorar la glucosilacion de la superficie celular.
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
WO2018224660A1
(en)
|
2017-06-09 |
2018-12-13 |
Armin Ehninger |
Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
CN120400338A
(zh)
|
2017-08-07 |
2025-08-01 |
约翰斯霍普金斯大学 |
用于评估和治疗癌症的方法和材料
|
|
JP7654240B2
(ja)
*
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
EP3695408B1
(en)
|
2017-10-02 |
2026-01-21 |
The Broad Institute, Inc. |
Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
US11117936B2
(en)
|
2017-11-10 |
2021-09-14 |
University of Pittsburg—Of the Commonwealth System of Higher Education |
Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
EP3744738A4
(en)
*
|
2017-11-29 |
2021-12-15 |
Guangzhou Cas Lamvac Biotech Co., Ltd. |
CHIMERA ANTIGEN RECEPTOR AND USES THEREOF
|
|
KR20200110326A
(ko)
|
2017-12-14 |
2020-09-23 |
블루버드 바이오, 인코포레이티드. |
Daric 인터류킨 수용체
|
|
CN111542547B
(zh)
|
2018-01-04 |
2024-02-13 |
美天施生物科技有限两合公司 |
对bdca2抗原具有特异性的嵌合抗原受体
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP3740569B1
(en)
|
2018-01-19 |
2023-07-26 |
Miltenyi Biotec B.V. & Co. KG |
Regulatory t cell expressing a chimeric antigen receptor
|
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
US20210079061A1
(en)
|
2018-02-26 |
2021-03-18 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
|
EP4495246A3
(en)
|
2018-03-01 |
2025-03-26 |
University of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
|
|
JP2021518160A
(ja)
|
2018-03-15 |
2021-08-02 |
ケーエスキュー セラピューティクス， インコーポレイテッド |
免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
AU2019249215A1
(en)
|
2018-04-06 |
2020-10-22 |
The Regents Of The University Of California |
Methods of treating EGFRvIII expressing glioblastomas
|
|
US20210155986A1
(en)
|
2018-04-13 |
2021-05-27 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
|
US20210079384A1
(en)
|
2018-04-13 |
2021-03-18 |
The Johns Hopkins University |
Non-invasive detection of response to a targeted therapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
US20190345261A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
|
WO2019222642A1
(en)
*
|
2018-05-18 |
2019-11-21 |
Senti Biosciences, Inc. |
Engineered immune cells and methods of use
|
|
CN120608151A
(zh)
|
2018-05-18 |
2025-09-09 |
约翰·霍普金斯大学 |
用于评估和/或治疗癌症的无细胞dna
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
EP3581200A1
(en)
|
2018-06-13 |
2019-12-18 |
GEMoaB Monoclonals GmbH |
Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12466869B2
(en)
|
2018-06-28 |
2025-11-11 |
Dana-Farber Cancer Institute, Inc. |
Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies
|
|
WO2020010229A1
(en)
*
|
2018-07-06 |
2020-01-09 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Car t cell therapy to target t cell specific cancers
|
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
CN110856724B
(zh)
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
包含核酸及car修饰的免疫细胞的治疗剂及其应用
|
|
EP3620464A1
(en)
|
2018-09-10 |
2020-03-11 |
Miltenyi Biotec GmbH |
Car cell having crosslinked disulfide bridge on antigen recognizing moiety
|
|
SG11202102108QA
(en)
|
2018-09-11 |
2021-04-29 |
Juno Therapeutics Inc |
Methods for mass spectrometry analysis of engineered cell compositions
|
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
EP3861024A4
(en)
*
|
2018-10-03 |
2022-12-21 |
University of Pittsburgh - of the Commonwealth System of Higher Education |
COVALENT ADAPTOR-SYNNOTCH AND CHIMERIC ANTIGEN RECEPTORS (CARS) FOR PROGRAMMABLE ANTIGEN TARGETING
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
US20220170097A1
(en)
*
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
CN113227358A
(zh)
|
2018-10-31 |
2021-08-06 |
朱诺治疗学有限公司 |
选择并刺激细胞的方法及用于所述方法的设备
|
|
CA3123084A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CN111454909B
(zh)
*
|
2019-01-22 |
2024-12-10 |
北京大学深圳研究生院 |
天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
|
|
CN113347991B
(zh)
|
2019-01-23 |
2024-07-30 |
美天施生物科技有限两合公司 |
用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US12453777B2
(en)
|
2019-03-20 |
2025-10-28 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
US20220193137A1
(en)
|
2019-04-04 |
2022-06-23 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
BR112021019571A2
(pt)
*
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
BR112021020999A2
(pt)
|
2019-05-04 |
2021-12-14 |
Inhibrx Inc |
Polipeptídeos de ligação à clec12a e usos dos mesmos
|
|
MX2021013590A
(es)
|
2019-05-08 |
2022-02-11 |
Inhibrx Inc |
Inmunoterapias dirigidas a cll-1.
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
CA3142108A1
(en)
|
2019-05-28 |
2020-12-03 |
Miltenyi Biotec B.V. & Co. KG |
Method for generation of genetically modified t cells
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
US12516315B2
(en)
|
2019-07-16 |
2026-01-06 |
The Regents Of The University Of California |
Genetically engineered immune effector cells comprising R-phycoerythrin-targeting receptor conjugated chimeric antigen receptor
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
US20220315894A1
(en)
|
2019-09-11 |
2022-10-06 |
Miltenyi Biotec B.V. & Co. KG |
Method for Transduction of T Cells in the Presence of Malignant Cells
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
KR20220143634A
(ko)
|
2019-10-16 |
2022-10-25 |
우모자 바이오파마 인코포레이티드 |
보편적 수용체 요법을 위한 레트로바이러스 벡터
|
|
IL291976A
(en)
*
|
2019-10-18 |
2022-06-01 |
Univ Boston |
cal-t structures and their uses
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
AU2020394441B2
(en)
|
2019-11-26 |
2025-11-13 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
EP4100027A1
(en)
|
2020-02-04 |
2022-12-14 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
IL295297A
(en)
|
2020-02-14 |
2022-10-01 |
Univ Johns Hopkins |
Methods and materials for assessing nucleic acids
|
|
EP3878464A1
(en)
|
2020-03-09 |
2021-09-15 |
Miltenyi Biotec B.V. & Co. KG |
Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
|
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
EP3881866A1
(en)
|
2020-03-16 |
2021-09-22 |
GEMoaB GmbH |
A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
|
|
KR20230004680A
(ko)
|
2020-04-17 |
2023-01-06 |
시티 오브 호프 |
Flt3-양성 악성 종양의 치료를 위한 flt3-표적화된 키메라 항원 수용체 변형 세포
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4153218A1
(en)
|
2020-05-20 |
2023-03-29 |
Miltenyi Biotec B.V. & Co. KG |
Compositions and methods for treating cancer expressing cd90 and cd326
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
EP4182339A1
(en)
|
2020-07-16 |
2023-05-24 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
|
TW202220677A
(zh)
|
2020-07-31 |
2022-06-01 |
日商中外製藥股份有限公司 |
含有表現嵌合受體之細胞的醫藥組成物
|
|
CA3189553A1
(en)
|
2020-08-19 |
2022-02-24 |
Astellas Pharma, Inc. |
Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
|
|
EP3964585A1
(en)
|
2020-09-03 |
2022-03-09 |
Miltenyi Biotec B.V. & Co. KG |
Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
|
|
EP4210733B1
(en)
*
|
2020-09-04 |
2024-11-06 |
Miltenyi Biotec B.V. & Co. KG |
System for inducible expression of an adapter in immune cells
|
|
EP4228660A4
(en)
*
|
2020-10-14 |
2025-02-26 |
Georgia Tech Research Corporation |
Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof
|
|
CN116802203A
(zh)
|
2020-11-04 |
2023-09-22 |
朱诺治疗学股份有限公司 |
从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
|
WO2022096425A2
(en)
|
2020-11-04 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor comprising an antigen binding domain specific for msln having a specificity for tumor cells
|
|
US20230405047A1
(en)
|
2020-11-09 |
2023-12-21 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
JP2024500847A
(ja)
*
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
WO2022204070A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
EP4333811A4
(en)
*
|
2021-05-07 |
2025-04-02 |
University of Florida Research Foundation, Inc. |
CAR-T CELL THERAPY METHOD
|
|
KR20240024806A
(ko)
*
|
2021-06-08 |
2024-02-26 |
비온테크 쎌 & 제네 테라피스 게엠베하 |
면역 작동자 세포의 활성화 및 표적화를 위한 물질 및 방법
|
|
CA3227128A1
(en)
*
|
2021-07-28 |
2023-02-02 |
Prescient Therapeutics Ltd |
Universal receptor immune cell therapy
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4176895A1
(en)
|
2021-11-08 |
2023-05-10 |
AvenCell Europe GmbH |
Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
|
|
JP2024544559A
(ja)
|
2021-11-15 |
2024-12-03 |
アーセルクス インコーポレイテッド |
Ｄドメイン含有ポリペプチドおよびその使用法
|
|
US20250017963A1
(en)
*
|
2021-12-07 |
2025-01-16 |
The Regents Of The University Of California |
Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors by engineered immune cells
|
|
WO2023187031A1
(en)
|
2022-04-01 |
2023-10-05 |
Miltenyi Biotec B.V. & Co. KG |
A system for drug-inducible expression of a polynucleotide
|
|
US20250295773A1
(en)
|
2022-05-10 |
2025-09-25 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116041545A
(zh)
*
|
2022-12-12 |
2023-05-02 |
南方医科大学 |
一种靶向荧光素或生物素的通用型car及其应用
|
|
WO2024178397A2
(en)
|
2023-02-24 |
2024-08-29 |
Elevatebio Technologies, Inc. |
Modified immune effector cells and methods of use
|
|
WO2024191918A1
(en)
|
2023-03-10 |
2024-09-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Anti-cd276 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
|
|
WO2024191919A1
(en)
|
2023-03-10 |
2024-09-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Anti-cd56 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
KR20260005358A
(ko)
|
2023-04-27 |
2026-01-09 |
밀테니 비오텍 비.브이. & 씨오. 케이지 |
항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자
|
|
WO2024223870A1
(en)
|
2023-04-27 |
2024-10-31 |
Miltenyi Biotec B.V. & Co. KG |
Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
|
|
WO2024241205A1
(en)
*
|
2023-05-19 |
2024-11-28 |
Seoul National University R&Db Foundation |
Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
EP4470555A1
(en)
|
2023-05-31 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
AU2024310260A1
(en)
|
2023-06-29 |
2025-12-11 |
Dispatch Biotherapeutics, Inc. |
Synthetic cytokine receptors
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025078492A1
(en)
|
2023-10-13 |
2025-04-17 |
Miltenyi Biotec B.V. & Co. KG |
Cd3-targeted nipah-pseudotyped lentiviral vector particles
|
|
WO2025087935A1
(en)
|
2023-10-26 |
2025-05-01 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025125231A1
(en)
|
2023-12-11 |
2025-06-19 |
Miltenyi Biotec B.V. & Co. KG |
Antigen - induced secretion of effector molecules of car t cells
|
|
WO2025149431A1
(en)
|
2024-01-08 |
2025-07-17 |
Miltenyi Biotec B.V. & Co. KG |
Anti cd276 adapter chimeric antigen receptor (car)
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|